Target Name: Integrin alpha1beta1 (VLA-1) receptor
NCBI ID: P5758
Review Report on Integrin alpha1beta1 (VLA-1) receptor Target / Biomarker Content of Review Report on Integrin alpha1beta1 (VLA-1) receptor Target / Biomarker
Integrin alpha1beta1 (VLA-1) receptor
Other Name(s): alpha1beta1 integrin | VLA-1

Understanding The Role of VLA-1 in Cell-Cell Adhesion and Tissue Repair

Integrin alpha1beta1 (VLA-1) receptor, also known as alpha1beta1 integrin, is a protein that plays a crucial role in cell-cell adhesion and tissue repair. It is a member of the integrin family, which consists of several different proteins that are involved in cell-cell and cell-matrix interactions. VLA-1 is a type of integrin that is expressed in many different tissues, including epithelial, muscle, and nervous cells.

One of the key functions of VLA-1 is its role in cell-cell adhesion. This is the process by which cells stick together to form tissues and organs. VLA-1 helps to regulate cell-cell adhesion by participating in several different signaling pathways. For example, it can interact with cadherins, which are proteins that are involved in cell-cell adhesion, and it can also interact with other proteins that are involved in cell-cell adhesion.

Another function of VLA-1 is its role in tissue repair. When cells are damaged or destroyed, VLA-1 helps to promote the formation of new tissues and organs. This is because VLA-1 can stimulate the production of new cells, as well as the formation of new blood vessels and other tissues.

VLA-1 is also involved in several other signaling pathways. For example, it can interact with the protein PDGF-BB, which is involved in cell proliferation and survival. It can also interact with the protein TGF-beta, which is involved in cell-cell adhesion and growth.

In addition to its role in cell-cell adhesion and tissue repair, VLA-1 is also considered a potential drug target. This is because several studies have suggested that VLA-1 may be involved in the development of certain diseases, such as cancer. For example, some studies have suggested that VLA-1 may be involved in the development of breast cancer, by helping to promote the growth and survival of cancer cells.

Another potential drug target for VLA-1 is its role in the development of autoimmune diseases. VLA-1 is involved in the immune response, and it has been suggested that it may be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Overall, VLA-1 is a protein that plays a crucial role in cell-cell adhesion and tissue repair. It is a potential drug target, and further research is needed to understand its role in these processes.

Protein Name: Integrin Alpha1beta1 (VLA-1) Receptor

The "Integrin alpha1beta1 (VLA-1) receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin alpha1beta1 (VLA-1) receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Integrin alpha2beta1 (VLA-2) receptor | Integrin alpha2beta3 Receptor | Integrin alpha3beta1 receptor | Integrin alpha4beta1 (VLA-4) receptor | Integrin alpha4beta7 (LPAM-1) receptor | Integrin alpha5beta1 (VLA-5) receptor | Integrin alpha5beta3 receptor | Integrin alpha6beta1 Receptor | Integrin alpha6beta4 receptor | Integrin alpha7beta1 Receptor | Integrin alpha9beta1 receptor | Integrin alphaEbeta7 receptor | Integrin alphaLbeta2 (LFA-1) receptor | Integrin alphaMbeta2 (MAC-1) Receptor | Integrin alphavbeta1 | Integrin alphavbeta3 (vitronectin) receptor | Integrin alphavbeta5 receptor | Integrin alphavbeta6 receptor | Integrin alphavbeta8 Receptor | Integrin Receptor | Integrin-linked kinase | Interferon | Interferon-alpha (IFN-alpha) | Interferon-gamma Receptor | Interleukin 17 | Interleukin 21 receptor complex | Interleukin 23 complex (IL-23) | Interleukin 35 | Interleukin-1 | Interleukin-1 receptor-associated kinase (IRAK) | Interleukin-12 (IL-12) | Interleukin-18 Receptor Complex | Interleukin-27 (IL-27) Complex | Interleukin-39 (IL-39) | Interleukin-7 receptor | Intraflagellar transport complex | Intraflagellar transport complex A | Intraflagellar transport complex B | Intrinsic Tenase Complex | INTS1 | INTS10 | INTS11 | INTS12 | INTS13 | INTS14 | INTS15 | INTS2 | INTS3 | INTS4 | INTS4P1 | INTS4P2 | INTS5 | INTS6 | INTS6L | INTS6L-AS1 | INTS6P1 | INTS7 | INTS8 | INTS9 | INTU | Invariant T Cell Receptor | INVS | Inward Rectifier Potassium Channel | IP6K1 | IP6K2 | IP6K3 | IPCEF1 | IPMK | IPO11 | IPO11-LRRC70 | IPO13 | IPO4 | IPO5 | IPO7 | IPO8 | IPO9 | IPO9-AS1 | IPP | IPPK | IPW | IQCA1 | IQCA1L | IQCB1 | IQCC | IQCD | IQCE | IQCF1 | IQCF2 | IQCF3 | IQCF5-AS1 | IQCF6 | IQCG | IQCH | IQCH-AS1 | IQCJ | IQCJ-SCHIP1 | IQCK | IQCM | IQCN | IQGAP1